7th November 2016
Innovative biotechnology company, Axim Biotechnologies Inc has appointed Grayling in the US to support its Investor Relations and Public Relations’ needs.
Axim Biotechnologies is engaged in the research and development, and production of pharmaceutical, nutriceutical and cosmetic products, as well as the procurement of genetically and nano-controlled active ingredients. The company’s particular focus is on the development of treatments for pain, spasticity, anxiety and other medical disorders using cannabinoids-based products. Pharmaceutical R&D aims to deliver systems and active pharmaceutical ingredients for treating conditions such as Parkinson's disease, Alzheimer's disease, restless leg syndrome and Crohn's disease.
Presently, the company is conducting clinical studies of MedChewRx, a pharmaceutical chewing gum containing cannabinoids. The company is in the process of getting FDA and EMA regulatory approval to launch this product in 2017, and it is in regard to this that Grayling is providing support.
Grayling’s efforts will be driven by New York based executive vice president, Lucia Domville. She says: “This is a fascinating company that is really pushing the boundaries with its research, and we are thrilled to be their partner.”
27th October 2016
PayPal's campaign devoted to people living in remote parts of Russia scoops a silver prize at the Golden Drum international festival of creativity.#WhereverYouAre is a documentary series...Read More
27th July 2016
Grayling has been shortlisted for a PRWeek Award 2016 in the category Public Sector for the campaign 'Protecting Consumers at Christmas'.The Awards presentation will take place on Tuesday 18th...Read More
17th February 2016
Hot on the heels of winning Africa’s ‘Best Newcomer Agency’ award, Grayling’s Africa expansion took another big step forward today with the appointment of the company’s first recruit in...Read More